These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10871312)

  • 1. A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor.
    Thibonnier M; Coles P; Conarty DM; Plesnicher CL; Shoham M
    J Pharmacol Exp Ther; 2000 Jul; 294(1):195-203. PubMed ID: 10871312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
    Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
    J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
    Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modelling of the vasopressin V2 receptor/antagonist interactions.
    Czaplewski C; Kaźmierkiewicz R; Ciarkowski J
    Acta Biochim Pol; 1998; 45(1):19-26. PubMed ID: 9701492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
    Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
    Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
    Cotte N; Balestre MN; Aumelas A; Mahé E; Phalipou S; Morin D; Hibert M; Manning M; Durroux T; Barberis C; Mouillac B
    Eur J Biochem; 2000 Jul; 267(13):4253-63. PubMed ID: 10866830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
    J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charged residues of the conserved DRY triplet of the vasopressin V1a receptor provide molecular determinants for cell surface delivery and internalization.
    Hawtin SR
    Mol Pharmacol; 2005 Oct; 68(4):1172-82. PubMed ID: 16049168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
    J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis.
    Jagerschmidt A; Guillaume N; Roques BP; Noble F
    Mol Pharmacol; 1998 May; 53(5):878-85. PubMed ID: 9584214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
    Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine.
    Glennon RA; Dukat M; Westkaemper RB; Ismaiel AM; Izzarelli DG; Parker EM
    Mol Pharmacol; 1996 Jan; 49(1):198-206. PubMed ID: 8569707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist.
    Frändberg PA; Doufexis M; Kapas S; Chhajlani V
    Biochem Biophys Res Commun; 2001 Mar; 281(4):851-7. PubMed ID: 11237737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
    Gimpl G; Postina R; Fahrenholz F; Reinheimer T
    Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands.
    Moretti L; Pentikäinen OT; Settimo L; Johnson MS
    J Struct Biol; 2004 Mar; 145(3):205-15. PubMed ID: 14960371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM; Wille S
    Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.